FDA Approves Xelstrym to Treat ADHD
Key takeaways: In March 2022, Xelstrym (dextroamphetamine) became the first FDA-approved amphetamine patch to treat ADHD in adults and children at least 6 years of age. Common side effects of Xelstrym include a smaller appetite, trouble sleeping, and headache. More serious side effects include dependence, heart problems, and serotonin syndrome. Xelstrym will probably be available in the second half of 2022. We don’t know how much it will cost yet.